About this trial
This study evaluates the feasibility and utility of contrast-enhanced ultrasound to provide real-time assessment of blood flow to the femoral head in infants undergoing surgical reduction for developmental dysplasia of the hip.
Eligibility criteria
Qualifiers
Males or females between 4 months and up to and including 24 months of age at the time of surgery.
Diagnosed with DDH.
Failed conservative treatment, or present with late-diagnosed DDH (where conservative treatment would not be appropriate to initiate at their age), and are undergoing closed or open reduction and spica casting.
Informed consent (parental permission)
Disqualifiers
> 24 months of age at the time of surgery.
Subjects with DDH who are successfully treated with conservative measures and do not require surgical reduction.
Previous open hip reduction of the affected side
Children with known complex congenital heart disease or unstable cardiopulmonary conditions (as noted in the package labeling for Lumason) including acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure or serious ventricular arrhythmias will be excluded.
Trial design
Treatments tested in this trial
- Intraoperative contrast-enhanced ultrasound (CEUS)
- Lumason
Treatment groups
Sponsors and collaborators
Children's Hospital of Philadelphia
Lead sponsor
Bracco Diagnostics, Inc
Collaborator
Pediatric Orthopaedic Society of North America
Collaborator